BriaCell Therapeutics Corp (BCTX) Plunges 29.55% Amid Public Offering Concerns

BriaCell Therapeutics Corp (BCTX) experienced a significant decline, with its share price falling to its lowest level since January 2025, marking an intraday drop of 29.55%.

BriaCell Therapeutics Corp has recently faced substantial stock price fluctuations due to several key developments. The company announced a public offering, which raised concerns among investors about potential dilution for existing shareholders, leading to a notable 22% drop in stock price. This financial move comes at a time when BriaCell is making significant strides in its clinical trials, particularly with its novel immunotherapy, Bria-OTS. The therapy has shown promising results, including the complete resolution of lung metastasis in a metastatic breast cancer patient and a 52% one-year survival rate in its Phase 2 study. These clinical achievements underscore the potential of Bria-OTS as a groundbreaking treatment in the field of cancer therapy. However, the company continues to grapple with financial challenges, including a lack of revenue and consistent losses, which add to the complexity of its current situation.